OSR Holdings Inc
OSRH
NASDAQ
Biotechnology
$0.32
USD
+0.03 (+11.66%)
At close: Aug 14, 2026, 4:00 PM EDT
Market Cap $9.94M
Volume 2.7M
About OSR Holdings Inc
OSR Holdings, Inc. operates as a global healthcare company. The company is headquartered in Bellevue, Washington and currently employs 22 full-time employees. The company went IPO on 2023-02-10. Through its subsidiaries, it is engaged in immuno-oncology, regenerative biologics, and medical device technologies. Its operating businesses include developing oral immunotherapies for the treatment of cancer, developing design-augmented (DA) biologics for age-related and other degenerative diseases and neurovascular intervention medical devices and systems distribution in Korea. Its subsidiaries include VAXIMM AG (Vaximm); RMC Co., Ltd. (RMC); Darnatein Co., Ltd. (Darnatein), and Woori IO Co., Ltd. (Woori IO). Vaximm is developing oral immunotherapies for the treatment of cancer and immunological disorders. RMC is a Korea-based neurovascular intervention medical device and systems distribution company. Darnatein is developing DA biologics for age-related and other degenerative diseases. Woori IO is a South Korea-based medical device company.
CEO
Mr. Kuk Hyoun Hwang
HQ
Bellevue, WASHINGTON, US
Founded
2023
Employees
22
Quantli Score
8.4
Outperform
Fin. Health
8.1
Profitability
7.6
Growth
9.0
Cash-Flow Q.
8.8
Key Metrics
5 metrics our research team weighs before forming a view on OSRH.
Based on Quantli research · SEC filings · as of Q1 2026
METRIC
VALUE
CHANGE
TREND (3Y)
Gross Margin (TTM)
22.2%
—
Operating Margin (TTM)
-726.1%
—
Net Margin (TTM)
-727.9%
—
ROE (TTM)
-15.0%
—
Free Cash Flow (TTM)
$-5.27M
—
Financial Snapshot
Revenue
$2.63M
— YoY
Gross Margin
22%
TTM
— YoY
Net Income
$-19.13M
— YoY
Operating Cash Flow
$-5.27M
— YoY
Key Statistics
Open
$0.31
Previous Close
$0.28
Day Range
$0.29 - $0.34
52 Week Range
$0.25 - $1.24
Volume
2.7M
Average Volume (10 Days)
680.0K
Dividend Yield
—
Valuation Measurement
Market Cap
$9.94M
P/E Ratio (TTM)
—
P/S Ratio (TTM)
3.78
Price / Book
0.08
Financial Highlights
Profit Margin
-727.9%
Return on Assets
-11.1%
Return on Equity
-15.0%
Revenue (TTM)
$2.63M
Net Income (TTM)
$-19.13M
Diluted EPS (TTM)
-$0.28
Total Cash (MRQ)
$1.57M
Levered FCF (TTM)
$-5.27M
Turn research into action
Knowing a stock is strong is the start. Knowing how to invest in it when you spot good research is good returns.
Earnings Calendar
Next Earnings
Estimated Q3 Release
Nov 10
Est. EPS
Adjusted consensus estimate
-$0.28